1. Home
  2. WVE vs LMAT Comparison

WVE vs LMAT Comparison

Compare WVE & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • LMAT
  • Stock Information
  • Founded
  • WVE 2012
  • LMAT 1983
  • Country
  • WVE Singapore
  • LMAT United States
  • Employees
  • WVE N/A
  • LMAT N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • LMAT Medical/Dental Instruments
  • Sector
  • WVE Health Care
  • LMAT Health Care
  • Exchange
  • WVE Nasdaq
  • LMAT Nasdaq
  • Market Cap
  • WVE 939.3M
  • LMAT 1.9B
  • IPO Year
  • WVE 2015
  • LMAT 2006
  • Fundamental
  • Price
  • WVE $6.54
  • LMAT $81.50
  • Analyst Decision
  • WVE Strong Buy
  • LMAT Buy
  • Analyst Count
  • WVE 11
  • LMAT 7
  • Target Price
  • WVE $20.91
  • LMAT $100.67
  • AVG Volume (30 Days)
  • WVE 1.7M
  • LMAT 188.6K
  • Earning Date
  • WVE 05-08-2025
  • LMAT 05-01-2025
  • Dividend Yield
  • WVE N/A
  • LMAT 0.97%
  • EPS Growth
  • WVE N/A
  • LMAT 30.45
  • EPS
  • WVE N/A
  • LMAT 1.97
  • Revenue
  • WVE $104,939,000.00
  • LMAT $226,256,000.00
  • Revenue This Year
  • WVE N/A
  • LMAT $11.00
  • Revenue Next Year
  • WVE N/A
  • LMAT $8.48
  • P/E Ratio
  • WVE N/A
  • LMAT $41.43
  • Revenue Growth
  • WVE N/A
  • LMAT 13.19
  • 52 Week Low
  • WVE $4.25
  • LMAT $71.42
  • 52 Week High
  • WVE $16.74
  • LMAT $109.58
  • Technical
  • Relative Strength Index (RSI)
  • WVE 42.23
  • LMAT 42.02
  • Support Level
  • WVE $6.30
  • LMAT $78.01
  • Resistance Level
  • WVE $8.39
  • LMAT $83.51
  • Average True Range (ATR)
  • WVE 0.66
  • LMAT 3.22
  • MACD
  • WVE 0.10
  • LMAT -0.83
  • Stochastic Oscillator
  • WVE 33.21
  • LMAT 23.07

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Share on Social Networks: